Open AccessRisk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study
Author(s) -
Stephan Linden,
Regina Bussing,
Paul Kubilis,
Tobias Gerhard,
Richard Segal,
Jonathan J. Shuster,
Almut G. Winterstein
Publication year - 2016
Publication title -
pediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.611
H-Index - 345
eISSN - 1098-4275
pISSN - 0031-4005
DOI - 10.1542/peds.2015-3199
Subject(s) - medicine , atomoxetine , hazard ratio , suicidal ideation , cohort , psychiatry , cohort study , retrospective cohort study , proportional hazards model , poison control , attention deficit hyperactivity disorder , confidence interval , injury prevention , methylphenidate , emergency medicine
Antidepressant effects on increased suicidality in children have raised public concern in recent years. Approved in 2002 for attention-deficit/hyperactivity disorder treatment, the selective noradrenalin-reuptake-inhibitor atomoxetine was initially investigated for the treatment of depression. In post-hoc analyses of clinical trial data, atomoxetine has been associated with an increased risk of suicidal ideation in children and adolescents. We analyzed whether the observed increased risk of suicidal ideation in clinical trials translates into an increased risk of suicidal events in pediatric patients treated with atomoxetine compared with stimulants in 26 Medicaid programs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom